Anaplastic Large-Cell Lymphoma (ALCL) is a rare and aggressive form of non-Hodgkin lymphoma that primarily impacts T-cells, a crucial part of the immune system. Here’s an overview of the ...

The occurrence rate of BIA-ALCL following breast augmentation with textured implants is variable, with the reported lifetime risk ranging from 1 in 355 to 1 in 86,029 patients.

Anaplastic large cell lymphoma (ALCL), a distinct subtype of T-cell non-Hodgkin lymphoma, has been the subject of vigorous research efforts over recent years. Investigations have focused on ...

The September 1, 2009, article by Laurent et al, entitled “Anaplastic Lymphoma Kinase–Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis” (J Clin Oncol 27:4211 ...

Prutsch, N., et al. (2024) STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. Cell Reports Medicine ...

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

Purpose Survivin, a member of the inhibitor of apoptosis (IAP) family, is not detected in normal adult tissues but is overexpressed in various cancers, including some types of lymphoma. The frequency ...

Women were followed for a median of 11.5 years. Of the 520 women with breast cancer tested for BRCA, 8.3%, or 43 patients were carriers of BRCA1 or BRCA2 mutations.

The approval was based on data from the randomized, double-blind, placebo-controlled ECHELON-3 trial (ClinicalTrials.gov Identifier: NCT04404283), which included 230 patients with R/R LBCL who ...

References: US Food and Drug Administration. FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.